Double immune attack: new combo aims to boost CAR-T success in tough lymphoma
NCT ID NCT07542678
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding a drug called glofitamab before and after standard CAR-T cell therapy can improve outcomes for 20 adults with high-risk, relapsed or refractory large B-cell lymphoma. Participants first receive glofitamab with chemotherapy, then CAR-T cells, followed by more glofitamab. The main goal is to see how many achieve complete remission by the end of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Glofitamab, gemcitabine, and oxaliplatin
What this could lead to
If successful, this combination approach could improve the chance of complete remission for patients with hard-to-treat lymphoma who are eligible for CAR-T therapy.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The added drugs also carry risks like infection and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED /REFRACTORY DLBCL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin
Berlin, State of Berlin, 12203, Germany
Contact
-
Universitätsklinikum Düsseldorf - Klinik für Hämatologie, Onkologie und klinische Immunologie
Düsseldorf, North Rhine-Westphalia, 40225, Germany
Contact
-
Universitätsklinikum Essen (AöR) - Westdeutsches Tumorzentrum Essen - Klinik für Hämatologie und Stammzellltransplantation
Essen, North Rhine-Westphalia, 45147, Germany
Contact
-
Universitätsklinikum Heidelberg - Innere Medizin V
Heidelberg, Baden-Wurttemberg, 69120, Germany
Contact
-
Universitätsklinikum Münster - Medizinische Klinik A
Münster, North Rhine-Westphalia, 48149, Germany
Contact